<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin Paulus, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew J Saxon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Friedman, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H93519170">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine is a psychostimulant that causes the release and blocks the reuptake of monoamine neurotransmitters, including dopamine, norepinephrine, and serotonin. Methamphetamine is most often smoked or snorted and is less commonly injected or ingested orally.
        </p>
        <p>
         Clinical manifestations of methamphetamine use include increased energy and alertness, euphoria, sympathetic nervous system activation, decreased need for sleep, weight loss, dry mouth leading to tooth decay, and chronic adverse mood and cognitive changes, including irritability, anxiety, aggression, panic, suspiciousness, and/or paranoia, hallucinations, executive dysfunction, and memory impairment. Methamphetamine can also exacerbate existing psychiatric symptoms [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The psychiatric diagnoses, methamphetamine abuse and methamphetamine dependence, were replaced by a single diagnosis, amphetamine-type substance and are found under the broader category of stimulant use disorders in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) [
         <a href="#rid2">
          2
         </a>
         ]. Although the crosswalk between the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and DSM-5-TR disorders is imprecise, methamphetamine dependence is approximately comparable to amphetamine-type substance use disorder, moderate to severe subtype, while methamphetamine abuse is similar to the mild subtype.
        </p>
        <p>
         This topic describes the epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis of methamphetamine use disorder. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of other stimulant use disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">
          "Cocaine use disorder: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106878.html" rel="external">
          "Stimulant use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H93519177">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine use varies geographically, but overall, amphetamine-type stimulants, which include methamphetamine, are the fastest rising drug of abuse worldwide [
         <a href="#rid3">
          3,4
         </a>
         ]. Amphetamine-type stimulants have become the second most widely used class of illicit drugs worldwide, with use increasing in Asia and Oceania [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2814504581">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         An estimated 4.7 million Americans (2.1 percent of the United States population) have reportedly tried methamphetamine at some time in their lives [
         <a href="#rid6">
          6
         </a>
         ]. The rate of methamphetamine use in the United States appears to be similar among males and females (0.32 versus 0.23 percent) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Methamphetamine use in the United States increased in the 1990s, reaching epidemic proportions in the early 2000s in the western and midwestern parts of the United States [
         <a href="#rid8">
          8
         </a>
         ]. As a consequence of regulations reducing access to methamphetamine precursors (eg,
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         ), United States prevalence indicators for the drug began to decrease in the mid-2000s [
         <a href="#rid9">
          9
         </a>
         ]. Between 2008 and 2014, the United States prevalence rate was found to be stable, with approximately 569,000 current users [
         <a href="#rid10">
          10-12
         </a>
         ].
        </p>
        <p>
         Evidence suggests that in the United States, the use of methamphetamine and overdose deaths due to methamphetamine are on the rise again [
         <a href="#rid13">
          13
         </a>
         ]. In the past decade, there have been alarming trends in the epidemiology and mortality of methamphetamine use in the United States. For example, a study investigating the trends in methamphetamine related deaths reported a 58-fold increase in methamphetamine-related deaths and a more than 50-fold increase in the age-adjusted mortality rate [
         <a href="#rid14">
          14
         </a>
         ]. This escalation is further complicated by the co-involvement of heroin or
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , ranging from 7 to 61 percent, with stark increases observed over the last decade. The co-use of methamphetamine and opioids contributed significantly to this mortality trend.
        </p>
        <p>
         In addition, according to a national survey, while past-year methamphetamine use increased by 43 percent (1.4 million [95% CI 1.2-1.6 million] to 2 million [95% CI 1.7-2.3 million]) in a five-year period ending in 2019, overdose deaths attributed to psychostimulants other than cocaine (largely methamphetamine) increased by 180 percent (ie, 5524 to 15,489) in the same time period [
         <a href="#rid13">
          13
         </a>
         ]. Data from law enforcement groups, welfare agencies, and substance use treatment programs indicate that methamphetamine continues to be a significant public health problem [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         During the coronavirus disease (COVID-19) pandemic, increased emergency department visits provide further evidence of increased methamphetamine use [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         In a United Nations report, the rates of methamphetamine use in other countries ranged from 0.2 to 1.3 percent of the population aged 15 to 64 years [
         <a href="#rid5">
          5
         </a>
         ]. This is similar to the rates in the United States. Over the past two decades, the use of amphetamine and methamphetamine became quite widespread in different regions across the world but was particularly dominant in East and Southeast Asia and North America [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15336338">
         <span class="h2">
          Comorbidity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with diagnosed chronic methamphetamine use show high rates of comorbid psychiatric disorders. For example, in a study of 189 individuals with methamphetamine dependence, co-occurring primary psychotic disorders were found among 29 percent, primary mood disorders were found among 32 percent and primary anxiety disorders were found among 27 percent [
         <a href="#rid18">
          18
         </a>
         ]. Further data supporting relationships between methamphetamine use disorder and psychiatric comorbidity include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a cohort study, an increased risk of psychotic symptoms was found in individuals who use methamphetamine versus the general population (odds ratio 1.3, 95% CI 1.03-1.72) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a sample of 214 individuals who used methamphetamine at least weekly and were enrolled in a clinical trial of a psychotherapeutic treatment for methamphetamine use, more than 70 percent had depressive symptoms of a severity meeting diagnostic criteria for major depression. Greater depressive symptom severity in the sample was associated with greater methamphetamine use [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one population-based sampling, elevated rates of panic disorder (adjusted prevalence ratio 4.7, 95% CI 1.1-19.0) and posttraumatic stress disorder (adjusted prevalence ratio 1.7, 95% CI 1.1-2.6) were found in individuals using methamphetamine compared with those who do not use methamphetamine [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately one-third to 40 percent of individuals with methamphetamine use disorder in samples studied have been assigned a lifetime diagnosis of attention deficit hyperactivity disorder [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         According to a national survey, the percentage of individuals using heroin who report use of methamphetamine increased from 9 percent to 44 percent over a five-year period ending in 2019 [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15336352">
         <span class="h1">
          HEALTH CONSEQUENCES
         </span>
        </p>
        <p class="headingAnchor" id="H24480181">
         <span class="h2">
          Mortality
         </span>
        </p>
        <p class="headingAnchor" id="H1373116195">
         <span class="h3">
          All-cause mortality and suicide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine use has been associated with increased risk of early mortality and suicide attempts [
         <a href="#rid24">
          24-26
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 1254 subjects with methamphetamine dependence who were admitted to a psychiatric center, the five-year rate of all-cause mortality was approximately 5 percent, an observed death rate 26 times greater than expected in females and six times greater than expected in males [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rates of self-reported suicide attempts have been found to be much higher in problem amphetamine users compared with non-drug-using peers of the same age, sex, and socioeconomic status [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3245822418">
         <span class="h3">
          Fatal overdose/fentanyl contamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine and cocaine users face a growing risk of fatal overdose from
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         contamination of the stimulants. Fentanyl, a highly potent synthetic opioid, can cause death via respiratory depression, particularly in opioid naïve people who have not developed tolerance. A study of a randomly selected national sample of one million urine drug test results from a wide variety of health care settings in the United States found that, in comparison with 2013, the rate of tests positive for cocaine that were also positive for nonprescribed fentanyl increased by 1850 percent, from 0.9 percent (95% CI 0.7-1.1) to 17.6 percent (95% CI 16.1-19.1) [
         <a href="#rid27">
          27
         </a>
         ]. The rate of tests positive for methamphetamine that were also positive for fentanyl increased by 798 percent, from 0.9 percent (95% CI 0.6-1.2) in 2013 to 7.9 percent (95% CI 7.1-8.7) in 2018.
        </p>
        <p class="headingAnchor" id="H24480095">
         <span class="h2">
          Cardiovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular complications such as malignant hypertension, arrhythmias, aortic dissection, myocardial infarction secondary to vasospasm, stroke, and cardiomyopathy are the leading causes of death among methamphetamine users [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         Among patients with cardiomyopathy in one hospital system, the proportion of cases associated with methamphetamine increased from 1.8 (in 2009) to 5.6 percent (in 2014) [
         <a href="#rid30">
          30
         </a>
         ]. In a retrospective cohort analysis, as many as 72 percent of methamphetamine users showed electrocardiogram abnormalities including tachyarrhythmias, right axis deviation, left ventricular hypertrophy, and QTc prolongation [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In a systematic review of 21 observational studies, methamphetamine-associated heart failure showed an increasing prevalence while affecting various racial, ethnic, and sociodemographic groups [
         <a href="#rid29">
          29
         </a>
         ]. Males were predominant in this group; up to 44 percent having preserved left ventricular ejection fraction. Methamphetamine-associated heart failure was found to be associated with elevated morbidity and worse heart failure symptoms as compared with non-methamphetamine-related heart failure. Positive predictors of recovery included female sex, methamphetamine abstinence, and guideline-directed heart failure therapy. Specific echocardiography chamber dimensions indicating lack of chronicity and degree of fibrosis on biopsy were associated with increased odds of improvement.
        </p>
        <p class="headingAnchor" id="H3017253535">
         <span class="h2">
          Stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adults who use methamphetamine have an approximately fivefold increased risk of a hemorrhagic stroke. As examples:
        </p>
        <p>
         A study described 250 adults who presented at a United States emergency department of a university medication center with an intracerebral hemorrhage between 2013 and 2015 [
         <a href="#rid32">
          32
         </a>
         ]. Forty-one of the patients had a positive toxicology test for methamphetamine. Hemorrhagic stroke patients who used methamphetamine were younger than stroke patients who did not (a mean of 52 versus 67 years) and had less premorbid neurologic disability but had higher diastolic blood pressure, longer intensive care unit and hospital stays, and no difference in neurologic disability from non-methamphetamine users at hospital discharge. Intracerebral hemorrhage is an important cause of premature disability and death associated with the methamphetamine use.
        </p>
        <p>
         Another review article described 98 published case reports of strokes in adults younger than 45 years associated with methamphetamine use [
         <a href="#rid33">
          33
         </a>
         ]. Outcomes of younger adults with methamphetamine-associated strokes were generally poor.
        </p>
        <p class="headingAnchor" id="H2713058446">
         <span class="h2">
          Renal dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine use appears to be associated with increased risk of renal dysfunction. In a meta-analysis including 9 trials and a total of 1884 subjects, methamphetamine use was found to increase both blood urea nitrogen and creatinine, respectively, raising the possibility that methamphetamine intoxication is linked with increased risk of renal dysfunction, potentially leading to organ failure [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H556216214">
         <span class="h2">
          Prenatal methamphetamine exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prenatal methamphetamine exposure is associated with lower birth weight [
         <a href="#rid35">
          35
         </a>
         ], shorter body length, smaller head circumference [
         <a href="#rid36">
          36
         </a>
         ], and neurocognitive abnormalities [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24480195">
         <span class="h2">
          Risky sexual behaviors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Users of methamphetamine typically have more sexual partners and are more likely to engage in risky sexual behaviors compared with controls [
         <a href="#rid38">
          38-40
         </a>
         ], partly because methamphetamine enhances libido. The odds of risky sex for heterosexual methamphetamine users is, on average, between 37 and 72 percent greater compared with non-methamphetamine users [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Some researchers suggest that risky behaviors and methamphetamine use are associative but not causal [
         <a href="#rid30">
          30
         </a>
         ]; however, other data are cause for concern. The number of reported primary and secondary syphilis cases associated with, among other drugs, methamphetamine more than doubled from 2013 to 2017 [
         <a href="#rid42">
          42
         </a>
         ]. A representative sample of 9
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade high school students in the United States found that lifetime methamphetamine use was associated with greater likelihoods of recent sexual intercourse, multiple recent sexual partners, and pregnancy [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H93519191">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine is a psychostimulant that causes an increase in the synapse of monoamine neurotransmitters including dopamine, norepinephrine, and serotonin via the following molecular mechanisms [
         <a href="#rid43">
          43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Redistribution of catecholamines from synaptic vesicles to the cytosol
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reversal of transport of neurotransmitter through plasma membrane transporters
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blocking the activity of monoamine transporters
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreasing the expression of dopamine transporters at the cell surface
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhibiting monoamine oxidase activity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing the activity and expression of tyrosine hydroxylase, the critical enzyme for synthesizing dopamine
        </p>
        <p>
        </p>
        <p>
         Methamphetamine use exerts its effects largely via the dopamine system. The consequence of the above processes is that dopamine becomes highly concentrated in the synaptic cleft and is available to postsynaptic uptake and subsequent signaling  (
         <a class="graphic graphic_figure graphicRef87703" href="/z/d/graphic/87703.html" rel="external">
          figure 1
         </a>
         ). A figure depicts the chemical structure of methamphetamine  (
         <a class="graphic graphic_figure graphicRef81294" href="/z/d/graphic/81294.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         Neuroimaging studies have shown that methamphetamine dependent individuals have:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower striatal and orbitofrontal dopamine D
         <sub>
          2
         </sub>
         /D
         <sub>
          3
         </sub>
         receptor availability [
         <a href="#rid44">
          44,45
         </a>
         ], which is associated with higher impulsivity [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower dopamine transporter and vesicular monoamine transporter type-2 in the striatum [
         <a href="#rid47">
          47
         </a>
         ] as well as in orbitofrontal and dorsolateral prefrontal cortex [
         <a href="#rid48">
          48
         </a>
         ], which persists even after protracted sobriety [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5974825">
         <span class="h2">
          Neurotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine use may lead to death of nerve cells as a consequence of multiple intracellular processes, but the evidence to date has not been conclusive.
        </p>
        <p>
         Research in animals suggests that human brain structures that are highly sensitive to oxidative stress, such as the hippocampus, may be affected by chronic methamphetamine use. Extensive studies in animals have shown that methamphetamine increases the blood brain barrier permeability, which most sensitively affects hippocampus [
         <a href="#rid50">
          50
         </a>
         ]. Several molecular mechanisms have been proposed to contribute to methamphetamine-induced neurotoxicity, including [
         <a href="#rid51">
          51
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxidative stress (eg, free radicals in the intracellular space)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excitotoxic mechanisms (eg, excessive glutamate)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroinflammation (eg, inflammation of the glia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ubiquitin proteasome system, dysfunctional recycling of proteins
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitochondrial dysfunction (eg, abnormal carbohydrate metabolism)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein nitration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endoplasmatic reticulum stress
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microtubule deacetylation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurotrophic factor dysfunction (eg, altered growth or development of neurons and glia)
        </p>
        <p>
        </p>
        <p>
         Changes in the blood brain barrier may enable the entry of pathogens into the brain parenchyma, thus decreasing the endogenous brain repair resources [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Postmortem studies of brains of methamphetamine uses have found some evidence of neurotoxicity [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1982576806">
         <span class="h2">
          Inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine may directly affect inflammatory processes via its binding to the toll-like receptor 4 (TLR-4) [
         <a href="#rid55">
          55
         </a>
         ]. This activation results in nuclear factor kappa B activation of microglia and proinflammatory cytokine response such as TNF-alpha, IL-6, and IL-1beta, which can be observed in increased levels in the central nervous system after acute or repeated drug use [
         <a href="#rid56">
          56
         </a>
         ]. These and other findings have been used to propose that inflammatory processes may play a significant role in the development of methamphetamine use disorder [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H93519205">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical effects of methamphetamine use are almost immediate, in part due to the routes of administration. The drug has been found most often to be smoked (68 percent) or snorted (31 percent), and less commonly to be injected (7 percent) or orally ingested (3 percent) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Methamphetamine rapidly enters well-perfused organs, including the brain, and has a half-life of approximately 9 to 13 hours [
         <a href="#rid59">
          59
         </a>
         ]. Methamphetamine can accumulate in the brain in concentrations up to 10 times greater than those in the plasma [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         The acute behavioral effects of methamphetamine include [
         <a href="#rid61">
          61
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased energy and alertness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased need for sleep
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Euphoria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased sexuality
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive talking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sweating
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disrupted sleep patterns
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tightened jaw muscles
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grinding teeth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of appetite, contributing to weight loss with chronic use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disorganized thinking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Itching
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal symptoms such as nausea, vomiting, or diarrhea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth leading to serious tooth decay with chronic use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Changes in mood consisting of irritability, anxiety, aggression, or panic
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other signs of sympathetic nervous system activation including pupillary dilatation, increased heart rate and other cardiovascular changes
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H599083730">
         <span class="h2">
          Psychosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A meta-analysis estimates that between 37 and 43 percent of individuals exposed to methamphetamine develop methamphetamine-induced psychotic disorder [
         <a href="#rid62">
          62
         </a>
         ]. Other studies suggest a bidirectional relationship between methamphetamine use and psychosis [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="local">
          'Comorbidity'
         </a>
         above.)
        </p>
        <p>
         The predominant symptoms are paranoia, persecutory delusions, auditory, visual, and tactile hallucinations. Methamphetamine-associated psychosis is often characterized by relatively long duration of psychosis and recurrence during periods of abstinence from the drug [
         <a href="#rid64">
          64-67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H458994893">
         <span class="h2">
          Catatonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         A systematic review concluded that clinicians should consider the potential relationship between methamphetamine use and catatonia [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5974923">
         <span class="h2">
          Cognitive effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence of the effect of chronic methamphetamine use on cognition is mixed [
         <a href="#rid69">
          69-73
         </a>
         ]. A longitudinal study of drug users in China suggested methamphetamine use was associated with increased cognitive impairment [
         <a href="#rid74">
          74
         </a>
         ]. Furthermore, a meta-analysis examining the neuropsychological effects of methamphetamine use disorder reported medium effect-sized deficits in episodic memory, executive functions, information processing, motor skills, language and visuoconstructional abilities (eg, having difficulties copying geometric figures) [
         <a href="#rid75">
          75
         </a>
         ]. Evidence suggests that cognitive measures of impulsivity associated with methamphetamine use do not improve with early abstinence [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         The clinical significance of cognitive impairments associated with long-term methamphetamine use is uncertain. Cognitive functioning in methamphetamine users has been found to fall overwhelmingly within the normal range when compared against normative data [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24480277">
         <span class="h2">
          Abstinence syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals experience an early abstinence syndrome after cessation of methamphetamine use, which manifests as one or more symptoms including [
         <a href="#rid77">
          77
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anhedonia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irritability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor concentration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperphagia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insomnia or hypersomnia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychomotor agitation or retardation
        </p>
        <p>
        </p>
        <p>
         Most of these symptoms appear to resolve within two weeks, although sleep disruption was reported for as long as four weeks in a small sample [
         <a href="#rid78">
          78
         </a>
         ]. This is consistent with 2016 findings suggesting rapid recovery of stored dopamine in some methamphetamine users who become abstinent [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H93519212">
         <span class="h1">
          ONSET AND COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a nationally representative United States survey, approximately five percent of respondents who used nonprescribed stimulants were estimated to become stimulant-dependent (DSM-IV) over a two-year period [
         <a href="#rid80">
          80
         </a>
         ]. Methamphetamine users were more likely to become dependent soon after onset of use compared with users of other stimulants.
        </p>
        <p>
         Furthermore, a six-year longitudinal study including 5034 12
         <sup>
          th
         </sup>
         grade students found that cocaine use or prescription stimulant misuse by age 18 years, but not a prior history of prescriptions stimulant use as prescribed for attention deficit hyperactivity disorder, are associated with onset of methamphetamine (or cocaine) use during you adulthood (age 19 to 24 years) [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">
          "Cocaine use disorder: Epidemiology, clinical features, and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         Little is known about the factors that influence the transition from use of methamphetamine to methamphetamine use disorder.
        </p>
        <p>
         Methamphetamine addiction is often characterized by repeated periods of intense use with intermittent sobriety and relapse [
         <a href="#rid82">
          82,83
         </a>
         ]. Although there are few long-term studies, an analysis of methamphetamine use in 474 individuals with chronic use over a 10-year period following initiation found that subjects used the drug an average of approximately 12 days per month [
         <a href="#rid84">
          84
         </a>
         ]. Analyses revealed five distinct trajectories of drug use:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing use, 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreasing use, 21 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High use, 22 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate use, 35 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low use, 7 percent
        </p>
        <p>
        </p>
        <p>
         There has been limited study of patient characteristics associated with treatment completion or outcome. In an analysis of 113,575 outpatient or residential treatment episodes for methamphetamine abuse or dependence from 1992 to 2002, noncompletion of treatment was associated with patient and clinical characteristics including [
         <a href="#rid85">
          85
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less than a high school education
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Younger age at treatment admission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent disability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater severity of methamphetamine use prior to treatment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methamphetamine injection
        </p>
        <p>
        </p>
        <p>
         Individuals who inject methamphetamine have been found to have particularly poor treatment outcomes in other studies. As an example, in a study of 974 methamphetamine users in outpatient treatment, patients who injected the drug, relative to those using other routes of administration, had [
         <a href="#rid86">
          86
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poorer treatment engagement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater drug use during treatment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower rates of treatment completion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater methamphetamine use 12 months following treatment
        </p>
        <p>
        </p>
        <p>
         Social pressure to use methamphetamine is a leading antecedent of relapse, based on our experience as well as a study of 60 patients in Taiwan [
         <a href="#rid87">
          87
         </a>
         ]. These interactions may be mediated by social adaptation, emotional stability, and education level.
        </p>
        <p class="headingAnchor" id="H93519219">
         <span class="h1">
          ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial examination of the patient should focus on the characteristics of current use (ie, the pattern, amount, and progression of recent use, and the route of administration). Given the clinical effects of methamphetamine use, the significant comorbidity of other psychiatric disorders, and the medical consequences of methamphetamine use, patients should also be assessed for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of depression, anxiety, psychosis, and suicidality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of other substances.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personality disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical conditions, including cardiovascular and central nervous system disease. Risk of stroke, seizures, heart disease (including cardiac valve abnormalities, angina, arrhythmias) should be evaluated. An electrocardiogram should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Socio-cultural context of methamphetamine use, which is important for identifying factors that might predict relapse (eg, regular contact with peers or partners who continue to use the drug). Evidence from 2016 suggests that the experience of childhood physical abuse may be means through which family history of substance use is associated with an earlier age of first drug use [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine toxicology tests can identify whether or not methamphetamine has been used, but no current laboratory or neuroimaging tests can be useful in diagnosing methamphetamine use disorder. No clinical tests can predict outcomes of these disorders following treatment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2133290">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The psychiatric diagnoses, methamphetamine abuse and methamphetamine dependence, were replaced by a single diagnosis, amphetamine-type substance and are found under the broader category of stimulant use disorders in DSM-5-TR [
         <a href="#rid2">
          2
         </a>
         ]. DSM-5-TR diagnostic criteria for methamphetamine use disorder are described below.
        </p>
        <p class="headingAnchor" id="H329439431">
         <span class="h2">
          DSM-5-TR criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         A problematic pattern of amphetamine-type substance, cocaine or other stimulant use (eg, methamphetamine use) leading to clinically significant impairment or distress, as manifested by two or more of the following within a 12-month period:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methamphetamine is often taken in larger amounts or over a longer period than was intended
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is a persistent desire or unsuccessful efforts to cut down or control methamphetamine use
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A great deal of time is spent in activities necessary to obtain methamphetamine, use methamphetamine, or recover from its effects
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Craving, or a strong desire or urge to use methamphetamine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent methamphetamine use resulting in a failure to fulfill major role obligations at work, school, or home
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continued methamphetamine use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of methamphetamine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Important social, occupational, or recreational activities are given up or reduced because of methamphetamine use
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent methamphetamine use in situations in which it is physically hazardous
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continued methamphetamine use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by methamphetamine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tolerance*
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Withdrawal*
        </p>
        <p>
        </p>
        <p>
         *These criteria are not considered to be met for those taking methamphetamine solely under appropriate medical supervision, such as for attention deficit hyperactivity disorder or narcolepsy.
        </p>
        <p>
         Specifiers for the diagnosis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In early remission – After full criteria for methamphetamine use disorder were previously met, none of the criteria for methamphetamine use disorder have been met (with the exception of craving) for at least three months but less than 12 months
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In sustained remission – After full criteria for methamphetamine use disorder were previously met, none of the criteria for methamphetamine use disorder have been met (with the exception of craving) during a period of 12 months or longer
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a controlled environment – If the individual is in an environment where access to methamphetamine is restricted
        </p>
        <p>
        </p>
        <p>
         The severity of methamphetamine use disorder at the time of diagnosis can be specified as a subtype based on the number of symptoms present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild: Two to three symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate: Four to five symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe: Six or more symptoms
        </p>
        <p>
        </p>
        <p>
         Most clinical trials of treatments for methamphetamine use were conducted in samples limited to patients with methamphetamine dependence in DSM-IV-TR or an earlier edition. Applying trial results to patients diagnosed with DSM-5-TR methamphetamine use disorder is imprecise; the most closely comparable patients are those with methamphetamine use disorder, moderate to severe subtype. Methamphetamine abuse is similar to the mild subtype of methamphetamine use disorder.
        </p>
        <p class="headingAnchor" id="H599083855">
         <span class="h2">
          Comorbid conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of a comorbid psychiatric disorder (most commonly, an anxiety, depressive, or psychotic disorder, or attention deficit hyperactivity disorder) may be difficult when the individual is actively using methamphetamine, because methamphetamine use can induce these symptoms. A drug-free period of at least a month is suggested before diagnosing one of these mental disorders [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="local">
          'Comorbidity'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2192570">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms related to methamphetamine use need to be distinguished from other mental and substance-use disorders that can present similarly.
        </p>
        <p class="headingAnchor" id="H601612380">
         <span class="h3">
          Psychosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The psychotic symptoms and disorganized thinking that can be seen with methamphetamine use can be indistinguishable from an acute psychotic episode due to other causes, including (see
         <a class="local">
          'Psychosis'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Schizophrenia or schizoaffective disorder (see
         <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">
          "Schizophrenia in adults: Clinical features, assessment, and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute manic episode (see
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other stimulant drugs including cocaine, phencyclidine, and synthetic cathinone ('bath salts') (see
         <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">
          "Cocaine use disorder: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/313.html" rel="external">
          "Phencyclidine (PCP) intoxication in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Factors that may be useful in distinguishing methamphetamine-induced psychosis from other causes include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age of onset – Earlier onset more likely to be due to primary psychotic disorder
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history – Positive family history for substance use disorder
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptom type – Nonauditory hallucinations more common than thought disorder with methamphetamine use
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H601612387">
         <span class="h3">
          Anxiety
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effects of methamphetamine intoxication or withdrawal can mimic an anxiety disorder.
        </p>
        <p class="headingAnchor" id="H3757757180">
         <span class="h3">
          Other psychiatric disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Differentiating a methamphetamine-use disorder from other mental or substance-use disorders can typically be informed by:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Collateral information from individuals close to the patient
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detailed history of prior episodes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine toxicology for methamphetamine and other drugs
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3711206420">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115010.html" rel="external">
          "Society guideline links: Stimulant use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H93519240">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Methamphetamine use varies geographically, but overall, amphetamine-type stimulants, which include methamphetamine, are the fastest rising drug of abuse worldwide. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular disease
         </strong>
         – Cardiovascular complications including malignant hypertension, arrhythmias, aortic dissection, myocardial infarction secondary to vasospasm, stroke, and cardiomyopathy are the leading causes of increased mortality in individuals who use methamphetamine. Cessation of methamphetamine use is associated with improvement in left ventricle function and decreased admission for heart failure at one-year follow-up. (See
         <a class="local">
          'Cardiovascular disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Methamphetamine has profound and multilevel effects on the dopamine system in the brain and increases the synaptic availability of this neurotransmitter following intake. Inflammatory processes are believed to contribute to the development of methamphetamine use disorder. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Clinical manifestations of methamphetamine use include intense euphoria, energy, increased libido, and excessive talkativeness. Other manifestations may include (see
         <a class="local">
          'Clinical manifestations'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Psychosis
         </strong>
         – Predominant symptoms include paranoia, persecutory delusions, auditory, visual, and tactile hallucinations. (See
         <a class="local">
          'Psychosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cognitive effects
         </strong>
         – Evidence on the effects of methamphetamine on cognitive performance is mixed. While some studies have identified neurocognitive deficits in users, their magnitude has not been clearly shown to be clinically significant. (See
         <a class="local">
          'Cognitive effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Abstinence syndrome
         </strong>
         – Individuals experience an early abstinence syndrome after cessation of methamphetamine use, which manifests as one or more symptoms including anhedonia, irritability, poor concentration, hyperphagia, sleep disturbance, or psychomotor changes. (See
         <a class="local">
          'Abstinence syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additionally, exposure to
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         (via drug contamination) and subsequent apnea and hypoxia, and increased risk of sexually transmitted disease due to risky sexual behavior are seen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Course
         </strong>
         – The course of methamphetamine addiction is prolonged and often characterized by repeated episodes of intense use, sobriety, and relapse. Individuals who inject the drug have been found to experience a worse course compared with those with other routes of administration. (See
         <a class="local">
          'Onset and course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment
         </strong>
         – Our assessment focuses on the severity of methamphetamine use, comorbid conditions, and psychosocial factors that may contribute to future relapse. (See
         <a class="local">
          'Assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnoses of methamphetamine abuse and methamphetamine dependence in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) were replaced by the single diagnosis, amphetamine-type substance use disorder under the broader category of stimulant use disorder. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McKetin R, Dawe S, Burns RA, et al. The profile of psychiatric symptoms exacerbated by methamphetamine use. Drug Alcohol Depend 2016; 161:104.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Degenhardt L, Mathers B, Guarinieri M, et al. Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy 2010; 21:347.
          </a>
         </li>
         <li class="breakAll">
          Unodc. World Drug Report 2010, United Nations Publication, Vienna 2010.
         </li>
         <li class="breakAll">
          UNODC. World Drug Report 2012, Contract No: E.12.XI.1, United Nations Publication, New York 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anglin MD, Burke C, Perrochet B, et al. History of the methamphetamine problem. J Psychoactive Drugs 2000; 32:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durell TM, Kroutil LA, Crits-Christoph P, et al. Prevalence of nonmedical methamphetamine use in the United States. Subst Abuse Treat Prev Policy 2008; 3:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawson RA, Anglin MD, Ling W. Will the methamphetamine problem go away? J Addict Dis 2002; 21:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell JC, Brecht ML. Methamphetamine: here we go again? Addict Behav 2011; 36:1168.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658, Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2011.
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-44, HHS Publication No. (SMA) 12-4713, Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2012.
         </li>
         <li class="breakAll">
          Center for Behavioral Health Statistics and Quality. Substance Abuse and Mental Health Services Administration (SAMHSA). Rockville, 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han B, Compton WM, Jones CM, et al. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry 2021; 78:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoopsick RA, Andrew Yockey R. Methamphetamine-Related Mortality in the United States: Co-Involvement of Heroin and Fentanyl, 1999-2021. Am J Public Health 2023; 113:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzales R, Mooney L, Rawson RA. The methamphetamine problem in the United States. Annu Rev Public Health 2010; 31:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ochalek TA, Cumpston KL, Wills BK, et al. Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic. JAMA 2020; 324:1673.
          </a>
         </li>
         <li class="breakAll">
          United Nations Office on Drugs and Crime, United Nations, Vienna 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res 2011; 186:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boden JM, Foulds JA, Newton-Howes G, McKetin R. Methamphetamine use and psychotic symptoms: findings from a New Zealand longitudinal birth cohort. Psychol Med 2023; 53:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay-Lambkin FJ, Baker AL, Lee NM, et al. The influence of depression on treatment for methamphetamine use. Med J Aust 2011; 195:S38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thoradeniya MR, Wessel EL, Pourmarzi D, et al. The prevalence of mental health disorders among young adults who use amphetamine-type stimulants, compared to young adults who do not. Drug Alcohol Rev 2021; 40:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strickland JC, Stoops WW, Dunn KE, et al. The continued rise of methamphetamine use among people who use heroin in the United States. Drug Alcohol Depend 2021; 225:108750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo CJ, Liao YT, Chen WJ, et al. Causes of death of patients with methamphetamine dependence: a record-linkage study. Drug Alcohol Rev 2011; 30:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WC, Chang HM, Huang MC, et al. All-cause and suicide mortality among people with methamphetamine use disorder: a nation-wide cohort study in Taiwan. Addiction 2021; 116:3127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaRue L, Twillman RK, Dawson E, et al. Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine. JAMA Netw Open 2019; 2:e192851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schürer S, Klingel K, Sandri M, et al. Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. JACC Heart Fail 2017; 5:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manja V, Nrusimha A, Gao Y, et al. Methamphetamine-associated heart failure: a systematic review of observational studies. Heart 2023; 109:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sliman S, Waalen J, Shaw D. Methamphetamine-Associated Congestive Heart Failure: Increasing Prevalence and Relationship of Clinical Outcomes to Continued Use or Abstinence. Cardiovasc Toxicol 2016; 16:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paratz ED, Zhao J, Sherwen AK, et al. Is an Abnormal ECG Just the Tip of the ICE-berg? Examining the Utility of Electrocardiography in Detecting Methamphetamine-Induced Cardiac Pathology. Heart Lung Circ 2017; 26:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swor DE, Maas MB, Walia SS, et al. Clinical characteristics and outcomes of methamphetamine-associated intracerebral hemorrhage. Neurology 2019; 93:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lappin JM, Darke S, Farrell M. Stroke and methamphetamine use in young adults: a review. J Neurol Neurosurg Psychiatry 2017; 88:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amanollahi A, Mehrabi Y, Sedighi M, et al. Assessment of renal function indexes in methamphetamine or tramadol intoxication adults to the emergency departments: a systematic review and meta-analysis. BMC Emerg Med 2023; 23:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harst L, Deckert S, Haarig F, et al. Prenatal Methamphetamine Exposure: Effects on Child Development–A Systematic Review. Dtsch Arztebl Int 2021; 118:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanjari Moghaddam H, Mobarak Abadi M, Dolatshahi M, et al. Effects of Prenatal Methamphetamine Exposure on the Developing Human Brain: A Systematic Review of Neuroimaging Studies. ACS Chem Neurosci 2021; 12:2729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunkler C, Lewis AJ, Almeida R. Methamphetamine exposure during pregnancy: A meta-analysis of child developmental outcomes. Neurosci Biobehav Rev 2022; 138:104714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson DR, Leamon MH, Flynn N. Epidemiology and public health Consequences of methamphetamine use in California's Central Valley. J Psychoactive Drugs 2002; 34:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forrest DW, Metsch LR, LaLota M, et al. Crystal methamphetamine use and sexual risk behaviors among HIV-positive and HIV-negative men who have sex with men in South Florida. J Urban Health 2010; 87:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zapata LB, Hillis SD, Marchbanks PA, et al. Methamphetamine use is independently associated with recent risky sexual behaviors and adolescent pregnancy. J Sch Health 2008; 78:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hittner JB. Meta-analysis of the association between methamphetamine use and high-risk sexual behavior among heterosexuals. Psychol Addict Behav 2016; 30:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidd SE, Grey JA, Torrone EA, Weinstock HS. Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2019; 68:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006; 31:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang GJ, Smith L, Volkow ND, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 2012; 17:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001; 158:2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee B, London ED, Poldrack RA, et al. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009; 29:14734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johanson CE, Frey KA, Lundahl LH, et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 2006; 185:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21:9414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martins T, Baptista S, Gonçalves J, et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res 2011; 1411:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu S, Zhu L, Shen Q, et al. Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. Behav Neurol 2015; 2015:103969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva AP, Martins T, Baptista S, et al. Brain injury associated with widely abused amphetamines: neuroinflammation, neurogenesis and blood-brain barrier. Curr Drug Abuse Rev 2010; 3:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekine Y, Ouchi Y, Sugihara G, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 2008; 28:5756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Northcutt AL, Cochran TA, et al. Methamphetamine Activates Toll-Like Receptor 4 to Induce Central Immune Signaling within the Ventral Tegmental Area and Contributes to Extracellular Dopamine Increase in the Nucleus Accumbens Shell. ACS Chem Neurosci 2019; 10:3622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bravo J, Magalhães C, Andrade EB, et al. The impact of psychostimulants on central and peripheral neuro-immune regulation: a scoping review of cytokine profiles and their implications for addiction. Front Cell Neurosci 2023; 17:1109611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohno M, Link J, Dennis LE, et al. Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies. Pharmacol Biochem Behav 2019; 179:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood E, Stoltz JA, Zhang R, et al. Circumstances of first crystal methamphetamine use and initiation of injection drug use among high-risk youth. Drug Alcohol Rev 2008; 27:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler JS, Volkow ND, Logan J, et al. Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. Neuroimage 2008; 43:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis 2002; 21:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart CL, Gunderson EW, Perez A, et al. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 2008; 33:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lecomte T, Dumais A, Dugré JR, Potvin S. The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Res 2018; 268:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hides L, Chan G, Dawe S, et al. Direction of the relationship between methamphetamine use and positive psychotic symptoms in regular methamphetamine users: evidence from a prospective cohort study. Br J Psychiatry 2021; 219:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant KM, LeVan TD, Wells SM, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol 2012; 7:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son JH, Latimer C, Keefe KA. Impaired formation of stimulus-response, but not action-outcome, associations in rats with methamphetamine-induced neurotoxicity. Neuropsychopharmacology 2011; 36:2441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean AC, Groman SM, Morales AM, London ED. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology 2013; 38:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan EE, Woods SP, Poquette AJ, et al. Visual memory in methamphetamine-dependent individuals: deficient strategic control of encoding and retrieval. Aust N Z J Psychiatry 2012; 46:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavnic B, Barnett BS, McIntire S, et al. Methamphetamine-associated catatonia: Case series and systematic review of the literature from 1943-2020. Ann Clin Psychiatry 2023; 35:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart CL, Marvin CB, Silver R, Smith EE. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology 2012; 37:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price KL, DeSantis SM, Simpson AN, et al. The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina. Am J Addict 2011; 20:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolliver BK, Price KL, Baker NL, et al. Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues. Am J Drug Alcohol Abuse 2012; 38:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homer BD, Solomon TM, Moeller RW, et al. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 2008; 134:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestor LJ, Ghahremani DG, Monterosso J, London ED. Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects. Psychiatry Res 2011; 194:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang TY, Fan TT, Bao YP, et al. Pattern and related factors of cognitive impairment among chronic methamphetamine users. Am J Addict 2017; 26:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott JC, Woods SP, Matt GE, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007; 17:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzpatrick RE, Robinson AH, Rubenis AJ, et al. Lack of longitudinal changes in cognition in individuals with methamphetamine use disorder during the first 6 weeks after commencing treatment. Am J Drug Alcohol Abuse 2021; 47:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newton TF, Kalechstein AD, Duran S, et al. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict 2004; 13:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mancino MJ, Gentry BW, Feldman Z, et al. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse 2011; 37:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boileau I, McCluskey T, Tong J, et al. Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence. Neuropsychopharmacology 2016; 41:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien MS, Anthony JC. Extra-medical stimulant dependence among recent initiates. Drug Alcohol Depend 2009; 104:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCabe SE, Schulenberg JE, Wilens TE, et al. Cocaine or Methamphetamine Use During Young Adulthood Following Stimulant Use for Attention-Deficit/Hyperactivity Disorder During Adolescence. JAMA Netw Open 2023; 6:e2322650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hser YI, Evans E, Huang D, et al. Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict Behav 2008; 33:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brecht ML, Huang D, Evans E, Hser YI. Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug Alcohol Depend 2008; 96:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hser YI, Huang D, Brecht ML, et al. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis 2008; 27:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brecht ML, Greenwell L, Anglin MD. Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992-2002). J Subst Abuse Treat 2005; 29:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawson RA, Gonzales R, Marinelli-Casey P, Ang A. Methamphetamine dependence: a closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment. Am J Addict 2007; 16:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yen CF, Chang YP. Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents. Psychiatry Clin Neurosci 2005; 59:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svingen L, Dykstra RE, Simpson JL, et al. Associations Between Family History of Substance Use, Childhood Trauma, and Age of First Drug Use in Persons With Methamphetamine Dependence. J Addict Med 2016; 10:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61:807.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14839 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26874915" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The profile of psychiatric symptoms exacerbated by methamphetamine use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26874915" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The profile of psychiatric symptoms exacerbated by methamphetamine use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20117923" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Meth/amphetamine use and associated HIV: Implications for global policy and public health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20117923" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Meth/amphetamine use and associated HIV: Implications for global policy and public health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20117923" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Meth/amphetamine use and associated HIV: Implications for global policy and public health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908000" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : History of the methamphetamine problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18655714" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prevalence of nonmedical methamphetamine use in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11831500" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Will the methamphetamine problem go away?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21875772" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Methamphetamine: here we go again?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21875772" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Methamphetamine: here we go again?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21875772" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Methamphetamine: here we go again?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21875772" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Methamphetamine: here we go again?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34550301" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36730885" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Methamphetamine-Related Mortality in the United States: Co-Involvement of Heroin and Fentanyl, 1999-2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20070191" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The methamphetamine problem in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32945832" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32945832" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21055832" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Psychiatric comorbidity in methamphetamine dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34134802" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Methamphetamine use and psychotic symptoms: findings from a New Zealand longitudinal birth cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21806517" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The influence of depression on treatment for methamphetamine use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33073466" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The prevalence of mental health disorders among young adults who use amphetamine-type stimulants, compared to young adults who do not.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16020027" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Implications of chronic methamphetamine use: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34052690" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The continued rise of methamphetamine use among people who use heroin in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21355920" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Causes of death of patients with methamphetamine dependence: a record-linkage study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22225671" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Extent of illicit drug use and dependence, and their contribution to the global burden of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33788344" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : All-cause and suicide mortality among people with methamphetamine use disorder: a nation-wide cohort study in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31026029" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28571597" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36456204" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Methamphetamine-associated heart failure: a systematic review of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26661075" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Methamphetamine-Associated Congestive Heart Failure: Increasing Prevalence and Relationship of Clinical Outcomes to Continued Use or Abstinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28110851" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Is an Abnormal ECG Just the Tip of the ICE-berg? Examining the Utility of Electrocardiography in Detecting Methamphetamine-Induced Cardiac Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31142634" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical characteristics and outcomes of methamphetamine-associated intracerebral hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28835475" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Stroke and methamphetamine use in young adults: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37568118" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Assessment of renal function indexes in methamphetamine or tramadol intoxication adults to the emergency departments: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34140080" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prenatal Methamphetamine Exposure: Effects on Child Development–A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34297546" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effects of Prenatal Methamphetamine Exposure on the Developing Human Brain: A Systematic Review of Neuroimaging Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35661684" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Methamphetamine exposure during pregnancy: A meta-analysis of child developmental outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12422943" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Epidemiology and public health Consequences of methamphetamine use in California's Central Valley.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20101468" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Crystal methamphetamine use and sexual risk behaviors among HIV-positive and HIV-negative men who have sex with men in South Florida.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19000240" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Methamphetamine use is independently associated with recent risky sexual behaviors and adolescent pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26866782" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Meta-analysis of the association between methamphetamine use and high-risk sexual behavior among heterosexuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30763294" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis - United States, 2013-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16951733" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The need for speed: an update on methamphetamine addiction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21747399" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Decreased dopamine activity predicts relapse in methamphetamine abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11729018" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19940168" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16518646" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12944350" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11717374" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21803344" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25861156" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208167" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Brain injury associated with widely abused amphetamines: neuroinflammation, neurogenesis and blood-brain barrier.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18509037" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Methamphetamine causes microglial activation in the brains of human abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640565" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31282647" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Methamphetamine Activates Toll-Like Receptor 4 to Induce Central Immune Signaling within the Ventral Tegmental Area and Contributes to Extracellular Dopamine Increase in the Nucleus Accumbens Shell.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37305435" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The impact of psychostimulants on central and peripheral neuro-immune regulation: a scoping review of cytokine profiles and their implications for addiction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30695700" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18368608" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Circumstances of first crystal methamphetamine use and initiation of injection drug use among high-risk youth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18708148" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11831497" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Patterns of methamphetamine abuse and their consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17851535" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Acute physiological and behavioral effects of intranasal methamphetamine in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30041133" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31950892" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Direction of the relationship between methamphetamine use and positive psychotic symptoms in regular methamphetamine users: evidence from a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21728034" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Methamphetamine-associated psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21775980" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Impaired formation of stimulus-response, but not action-outcome, associations in rats with methamphetamine-induced neurotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22948978" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22311530" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Visual memory in methamphetamine-dependent individuals: deficient strategic control of encoding and retrieval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37459499" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Methamphetamine-associated catatonia: Case series and systematic review of the literature from 1943-2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22089317" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Is cognitive functioning impaired in methamphetamine users? A critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21838844" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22257306" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18298273" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22047731" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28177556" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pattern and related factors of cognitive impairment among chronic methamphetamine users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17694436" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Neurocognitive effects of methamphetamine: a critical review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33524275" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Lack of longitudinal changes in cognition in individuals with methamphetamine use disorder during the first 6 weeks after commencing treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15370944" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Methamphetamine abstinence syndrome: preliminary findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21219261" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26321315" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19515516" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Extra-medical stimulant dependence among recent initiates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37432689" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Cocaine or Methamphetamine Use During Young Adulthood Following Stimulant Use for Attention-Deficit/Hyperactivity Disorder During Adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18790574" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18329825" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18956525" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Contrasting trajectories of heroin, cocaine, and methamphetamine use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16311182" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992-2002).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17661197" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Methamphetamine dependence: a closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15679544" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27427901" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Associations Between Family History of Substance Use, Childhood Trauma, and Age of First Drug Use in Persons With Methamphetamine Dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289279" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
